AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
Upon exercise of the option, AbbVie would pay Aldeyra a $100M upfront cash payment, less previously paid option fees of $6M. In addition, Aldeyra would be eligible to receive up to $300 million in ...
Patent expirations from Brukinsa’s existing competitors may bring biosimilar drugs into the field before Brukinsa reaches its full commercial potential. BeiGene may lose the lawsuit to AbbVie over ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback